Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Elixirgen Therapeutics Announces Dosing of First and Second Participants in its COVID-19 Vaccine Phase 1/2 Clinical Trial at Fujita Health University

prnewswireMay 26, 2021

Tag: RNA vaccine , SARS-CoV-2 , COVID-19 , EXG-5003

PharmaSources Customer Service